This preparation eye drop is indicated in:

• Acute and chronic allergic non-infectious conjunctivitis and keratitis with severe swelling and intravascular injection.
• Non-infectious inflammation of the anterior segment of the eye (including anterior uveitis, episcleritis, and scleritis).
• Post-operative irritative conditions after strabismus, cataract, and glaucoma surgery with supplementary antimicrobial therapy.

Fluorometholone is thought to act by the induction of phospholipase A2 inhibitory proteins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. On the other hand, Tetrahydrozoline is an alpha agonist that constricts the conjunctival blood vessels and thereby relieves the redness of the eye.

Use in adults: Instill 1 drop into the conjunctival sac 2-3 times daily. The dose may be increased for severe cases and adult patients to 1 drop hourly for the first one to two days.

Use in children: Safety and effectiveness in children below 2 years of age have not been established.

Tetrahydrozoline may interact with antidepressant drugs that inhibit the Monoamine Oxidase (MAO) enzyme, such as Isocarboxazid, phenelzine and its sulfate derivative, Toloxatone, Tranylcypromine and its sulfate derivative, etc.

It is contraindicated in Infectious conjunctivitis or keratitis. Injuries or ulcerous processes of the cornea. Glaucoma. Diseases associated with stromal damage of the cornea or sclera. Dry eyes.

Mild burning sensation, reversible increase in intraocular pressure, reactive hyperemia, cataract and corneal defects, glaucoma, systemic effects (with chronic use).

There are no adequate and well-controlled studies of Fluorometholone & Tetrahydrozoline in pregnancy or while breastfeeding. Therefore, this combination should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.

Avoid prolonged use. This preparation should be used after a careful risk-benefit evaluation in patients with severe blood circulation diseases, metabolic disturbances, those under treatment with MAOIs and other potentially hypertensive drugs, and those with a history of cataract, herpes simplex infection, or rhinitis sicca.

When the product is used as directed, there is almost no likelihood of an overdose. No information on overdosage with fluorometholone is available. Overdosage with fluorometholone is unlikely to cause acute problems. The symptoms of acute overdosage with tetrahydrozoline are CNS, cardiac, and psychiatric disturbances, mydriasis, cyanosis, and fever. CNS functions may be inhibited under certain circumstances.

The following measures are possible in case of accidental ingestion and the occurrence of symptoms of intoxication: administration of activated charcoal, gastric lavage, artificial ventilation with oxygen, and use of phentolamine to lower blood pressure (5 mg in saline solution, given IV). Vasopressors are contraindicated. Antipyretic and anticonvulsive therapy can be administered as necessary.

Ophthalmic Steroid preparations

Keep out of the reach of children. Store in a cool, dry place, away from heat and direct light. Do not use more than 4 weeks after opening.